Oncology & Hematology Coding Alert

Reader Questions:

Verify V70.7 Placement for Healthy Volunteer

Question: I'm confused by Medicare Transmittal 1901. How does it change our current outpatient clinical trial coding? New York Subscriber Answer: Essentially, the transmittal clarifies proper ICD-9 coding. CMS provides additional detail that has already been stated in Medicare Claims Processing Manual (MCPM), Chapter 32, Section 69.7, and adds this information to Section 69.6 for healthy trial volunteer claims. Transmittal 1901 (CR 6776) adds text to Section 69.6, stating that you should report V70.7 (Examination of participant in clinical trial) as the primary diagnosis for healthy control group volunteers. Oncology trials often don't involve healthy volunteers, though, so the rule may not affect most of your trial coding. For ill trial members, you should still use V70.7 as the secondary diagnosis, listing the disease treated as primary. And remember to designate investigational services using modifier Q0 (Investigational clinical service provided in a clinical research study that is in an approved [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All